Navigation Links
Pipeline of Pulmonary Arterial Hypertension Market (PAH) Reviewed for H1 2016 in New Report
Date:4/29/2016

PUNE, India, April 29, 2016 /PRNewswire/ --

ReportsnReports.com adds "Pulmonary Arterial Hypertension - Pipeline Review, H1 2016" market research report that provides an overview of the PAH therapeutic pipeline, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.

Companies discussed in this Pulmonary Arterial Hypertension Pipeline Review, H1 2016 report include APT Therapeutics, Inc., Arena Pharmaceuticals, Inc., Asahi Kasei Pharma Corp., Ascendis Pharma A/S, Bial - Portela & Ca, S.A., Bristol-Myers Squibb Company, Carolus Therapeutics, Inc., Celsion Corporation, Complexa, Inc., Corridor Pharmaceuticals Inc., Cytokinetics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Insmed Incorporated, INVENT Pharmaceuticals, Inc., Johnson & Johnson, Kowa Company, Ltd., Mallinckrodt Plc, Mezzion Pharma Co. Ltd., miRagen Therapeutics, Inc., Morphogen-IX Limited, Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis AG, Peloton Therapeutics, Inc., PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc., Pluristem Therapeutics Inc., Proteo, Inc., Pulmokine, Inc., Reata Pharmaceuticals, Inc., Respira Therapeutics, Inc., Selten Pharma, Inc, Silence Therapeutics Plc, SteadyMed Therapeutics, Inc., Suda Ltd and Toray Industries, Inc.

Complete report on H1 2016 pipeline review of Pulmonary Arterial Hypertension with 62 market data tables and 16 figures, spread across 202 pages is available at http://www.reportsnreports.com/reports/538046-pulmonary-arterial-hypertension-pipeline-review-h1-2016.html .

The report also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Drug profiles discussed in this research report includes Antibody for Pulmonary Arterial Hypertension, Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension, APT-602, bardoxolone methyl, beraprost sodium ER, beraprost sodium SR, BIA-51058, BMP-9, CT-2009, CXA-10, Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension, fasudil, imatinib mesylate, INS-1009, INV-240, JNJ-26993135, lisuride, MFC-001, MFC-002, nitric oxide, Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension, Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension, PB-1046, PB-1120, pitavastatin NP, PK-10453, PK-10571, PLX-PAD, PT-2977, QCC-374, R-190, ralinepag, RT-234, selexipag, selonsertib, sirolimus albumin-bound, Small Molecule for Pulmonary Arterial Hypertension, Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction, Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension, Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension, Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension, Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension, SPI-054, SPI-183, SUD-004, Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction, Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension, tacrolimus, tadalafil, tiprelestat, tocilizumab, TR-422, treprostinil, treprostinil diolamine, TXA-127, ubenimex and udenafil.

Order a copy of this PAH pipeline report for H1 2016 @ http://www.reportsnreports.com/Purchase.aspx?name=538046 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension and reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Another newly published market research report titled on Portal Hypertension - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Portal Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Portal Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Portal Hypertension Pipeline market research report of 73 pages is available at http://www.reportsnreports.com/reports/538071-portal-hypertension-pipeline-review-h1-2016.html .

Explore more reports on Pharmaceuticals.

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com


'/>"/>
SOURCE ReportsnReports
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Osteoarthritis Pipeline Market H1 2016 Global Review Report
2. Contact Lenses Market Medical Devices Pipeline Assessment 2016 Research Report
3. Frontier Pharma Report: Chronic Obstructive Pulmonary Disease (COPD) Market - Which Molecular Targets Appear Most Frequently in the Pipeline? - Research and Markets
4. Frontier Pharma: Ovarian Cancer Report - What Are The Current Unmet Needs That The Pipeline Needs To Address - Research and Markets
5. Pipeline of Polycythemia Vera Market Reviewed for H1 2016
6. Despite its Weak Pipeline, Schizophrenia Market May Benefit from Drugs Used in Similar Indications, Says GBI Research
7. H1 2016 Lyme Disease Pipeline Market Research Report
8. Substance Abuse Treatment Pipeline Dominated by Nicotine and Alcohol Addiction Treatments, Says GBI Research
9. Peripheral Neuropathy (Sensory) Market Pipeline Global Review H2 2015
10. Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
11. Anthrax Market Pipeline Global Review Research Report for H2 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):